154,

155.

156.

157.

158.

159.

160.

161.

162.

163.

164.

165.

166.

167.

Deutsch, 8.L, Olendorf, W.IL, Davis, K.L.: Brain uptake indices of guanidine
and 4-aminopyridine. Life Sci 34:2279-2280, 1984.

Small, N.E., Mohs, R.C., Halperin, R., Rosen, W.G., Masterson, C., Kendler,
K.S., Horvath, T.B., and Davis, K.L.: A study of the reliability of reported
premorbid adjustment in schizophrenic patients. Biol Psychiatry 19:203-
211, 1984.

Davis, K.L., Mohs, R.C. and Horvath, T.B.: Schizophrenia biological research
centers in the Veterans Administration. Psychiatric Annals 14:269-271,
1984,

Schleiffer, S.J., Keller, S.E., Meyerson, A.T., Raskind, M.J., Davis, K.L, and
Stein, M.: Lymphocyte function in major depressive disorder Arch
Gen Psychiatry 41:484-486, 1984,

Mohs, R.C., Rosen, W.G., and Davis, K.L.: An instrument for assessing
treatment efficacy. Psychopharmacol Bull 19:448-450, 1983.

Davis, B.M., Davis, K.L., Mohs, R.C., Mathé, A.A., Rothpearl, A.B, Johns,
C.A., Levy, M.L, and Horvath, T.B. Methodological problems in evaluating
Prolactin response to dopamine agonists in schizophrenia. Arch Gen
Psychiatry 42:259-26 4, 1985.

Davis, K.L., Johns, C.A., Mohs, R.C., and Greenwald, B.S. Reply to letter, Re:
Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer's
disease. N, Engl J. Med 309:555-556, 1983.

Haroutunian, V., Kanof, P. and Davis, K.L.: Pharmacological alleviations of
cholinergic lesion induced memory deficits in rats, Life Sei 37:945- |
952, 1985.

Mohs, R.C., Horvath, T.B., and Davis, K.L. Alzheimer's disease: V A research
brings hope to the elderly. VA Practitioner 1:48-51, 1984.

Losonezy, M.F., Mohs, R.C., and Davis, K.L. Seasonal variations of human
lumbar CSF neurotransmitter metabolite concentrations, Psychiatry
Research 12:79-87, 1984.

Fiori, M. and Davis, K.L. Possible clinical applications of laboratory tests in
depression. J. Clin Psychiatry 45:6-11, 1984.

Johns, C.A., Haroutunian, V., Greenwald, B.S., Mohs, R.C., Davis, B.M., Kanof,
P., Horvath, T.B., Davis, K.L. Development of cholinergic drugs for
the treatment of Alzheimer's disease. Drug Development Research 5(1):
77-96, 1985.

Hollander, E., Mohs, R.C., Davis, K.L, Antemortem markers of Alzheimer's

disease. Neurobiology of Aging (in press),

Mohs, R.C., Davis, B.M., Johns, C.A., Mathé, A.A., Greenwald, B.S., Horvath,
T.B., and Davis, K.L.: Oral physostigmine treatment of patients with AD,

American Journal Psychiatry 142:28-33, 1985.

16

50287595